compounding glp-1 fda Compounding: When Innovation May Mean Liability FDA ban on compounded tirzepatide:

DPP-4 is an enzyme that rapidly breaks down GLP-1 and related hormones

It is studied as a KLOW 80mg peptide blend for multi-pathway research bringing tissue-repair, angiogenic, and anti-inflammatory peptides together at fixed ratios so a research model can be exposed to all four compounds at once, without reconstituting four separate vials

But the specifics of this process - including how much time pharmacies have to exhaust existing inventory, whether existing patient prescriptions can continue to be filled, and how shortage status applies to specific dosage forms versus the drug as a whole - have been the subject of significant legal debate and litigation

You can also read our complete introduction to peptide therapy and our peptide therapy FAQ for a broader grounding before your consultation

doi: 10.1111/apa.15168 53